Ginkgo Bioworks Holdings EBITDA 2020-2022 | DNA
Ginkgo Bioworks Holdings annual and quarterly EBITDA history from 2020 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Ginkgo Bioworks Holdings EBITDA for the quarter ending March 31, 2022 was $-0.665B, a 1191.67% increase year-over-year.
- Ginkgo Bioworks Holdings EBITDA for the twelve months ending March 31, 2022 was $-2.428B, a 2727.01% increase year-over-year.
- Ginkgo Bioworks Holdings 2021 annual EBITDA was $-1.799B, a 1360.98% increase from 2020.
- Ginkgo Bioworks Holdings 2020 annual EBITDA was $-0.123B, a 102.43% increase from 2019.
- Ginkgo Bioworks Holdings 2019 annual EBITDA was $-0.061B, a INF% decline from .
Ginkgo Bioworks Holdings Annual EBITDA
(Millions of US $) |
| 2021 |
$-1,799 |
| 2020 |
$-123 |
| 2019 |
$-61 |
Ginkgo Bioworks Holdings Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-665 |
| 2021-12-31 |
$-1,731 |
| 2021-09-30 |
$-27 |
| 2021-06-30 |
$-5 |
| 2021-03-31 |
$-51 |
| 2020-12-31 |
|
| 2020-09-30 |
$-34 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.223B |
$0.314B |
|
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
|
